Thursday, June 24, 2021
Home Latest Pharma-News

Latest Pharma-News

Vaccitech announces successful recruitment and vaccination for two phase 2 Universal influenza studies FLU009 and FLU010 for the treatment and prevention of cancer...

Nov 25, 2019: Vaccitech Ltd, a clinical-stage T cell immunotherapy company develop the products for the treatment and prevention of  cancer and infectious...

FDA approves new system for the delivery of tympanostomy tubes under local anesthesia to treat ear infection

Nov 25, 2019 :Tusker Medical recievied approval from The U.S. Food and Drug Administration for the delivery of tympanostomy tubes (ear tubes)...

Takeda says cancer drug Alunbrig (brigatinib) results in longer benefit vs crizotinib After Two Years of Follow-Up

Nov 23, 2019: Data updated by Takeda Pharmaceutical from its Phase 3 ALTA-1L trial  evaluating ALUNBRIG versus crizotinib in adults with advanced...

Roche presents pivotal First Phase III cancer immunotherapy Tecentriq in combination with Avastin to show an improvement in liver cancer patients

Nov 22,2019: Roche presents positive results from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment  of...

ViiV Healthcare announces exclusive licensing agreement with NIH to develop investigational bNAb N6LS for treatment & prevention of HIV-1

Nov 21,2019 : ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced...

BioMarin seeks European marketing Authorization for valoctocogene roxaparvovec to treat severe hemophilia A

Nov 21,2019: BioMarin Pharmaceutical Inc. announced that the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for...

Amgen Completes Acquisition Of Otezla® (apremilast) for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis

Nov. 21, 2019: Amgen announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for...

Aquestive Therapeutics’ treatment approved by FDA for neurological disorder amyotrophic lateral sclerosis (ALS)

Nov 22, 2019: The U.S. Food and Drug Administration approved Aquestive Therapeutics' treatment for neurological disorder amyotrophic lateral sclerosis (ALS).

AbbVie to present Ibrutinib (IMBRUVICA®) plus venetoclax (VENCLEXTA®/ VENCLYXTO®) , in American Society of Hematology (ASH) Annual Meeting for the treatment of...

Nov 21, 2019 : AbbVie, a research-based global biopharmaceutical company announced that between Dec 7- 10  in American Society of Hematology (ASH) Annual Meeting...

Harpoon Therapeutics and AbbVie Announce an elite worldwide option and license transaction for HPN217 and Expand Existing Discovery Collaboration

Nov 21, 2019: Harpoon Therapeutics, Inc. a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc, a...

XCOPRI (cenobamate tablets) approved by FDA for the treatment partial-onset seizures in adults

Nov 21, 2019: SK Life Science new option to treat adults with partial-onset seizures, XCOPRI (cenobamate tablets) approved by FDA which has...

US Food and Drug Administration (FDA) approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Nov 21,2019: AstraZeneca announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukaemia (CLL)...

Most Read

Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of OS and PFS

June 22, 2021: Merck known as MSD outside the United States and Canada announced that the pivotal Phase 3 KEYNOTE-826 trial investigating...

EU approve Koselugo for children with neurofibromatosis & plexiform neurofibromas

June 22, 2021: "AstraZenecaand MSD's Koselugo (selumetinib) has been granted conditional approval in the EU for the treatment of symptomatic, inoperable plexiform neurofibromas (PN)...

FDA Approves First Oral Blood Thinning Medication for Children

June 21, 2021: The U.S. FDA approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years...

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine

JUNE 22, 2021: "Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, have...